drugset
drugset / Trial / NCT04086758

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

NCT04086758 ↗

Phase 1 Completed 12 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Timeline

Start
2019-10-18
Primary completion
2021-01-22
Completion
2021-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject zolbetuximab Monoclonal antibody — Intravenous

Indications

gastroesophageal adenocarcinoma